OnabotulinumtoxinA: A Meta-Analysis of Duration of Effect in the Treatment of Glabellar Lines

被引:42
作者
Glogau, Richard [2 ]
Kane, Michael [3 ]
Beddingfield, Frederick [4 ]
Somogyi, Christine
Lei, Xiaofang
Caulkins, Carrie
Gallagher, Conor [1 ]
机构
[1] Allergan Pharmaceut Inc, Med Affairs, Irvine, CA 92612 USA
[2] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA
[3] Manhattan Eye Ear & Throat Hosp, New York, NY 10021 USA
[4] Univ Calif Los Angeles, David Geffen Sch Med, Dept Dermatol, Los Angeles, CA 90095 USA
关键词
TOXIN TYPE-A; BOTULINUM-TOXIN; DOUBLE-BLIND; LONG-TERM; SAFETY; EFFICACY; BLEPHAROSPASM; COMBINATION; MULTICENTER; INJECTION;
D O I
10.1111/j.1524-4725.2012.02582.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
BACKGROUND Duration of effect of aesthetic treatments with botulinum toxin potentially influences subject satisfaction, treatment frequency, and annual costs, but quantitative outcomes for measuring duration of effect and correlations with subject satisfaction have yet to be fully elucidated. METHODS AND MATERIALS Phase III clinical trials with similar designs were identified and their data pooled to ascertain duration of clinical effect of onabotulinumtoxinA in glabellar muscles. Duration was calculated using the KaplanMeier method for investigator-rated Facial Wrinkle scale (FWS) scores and subject global assessment (SGA) of glabellar lines. Responders were determined according to FWS score at maximum contraction and at repose 30 days after injection. RESULTS Data from four trials with 621 onabotulinumtoxinA-treated (20 U) subjects were analyzed, 523 of these (84.2%) were identified as day-30 responders on the FWS at maximum contraction. Pooled median duration of effect for day-30 responders was 120 days for FWS at maximum contraction and 131 days for FWS at repose. Higher day 30 SGA scores were correlated with a greater duration of effect on dynamic, but not static lines. CONCLUSION Treatment of glabellar lines with 20 U of onabotulinumtoxinA resulted in sustained clinical benefit for 4 months in more than 50% of responders; subject satisfaction increased with duration of effect.
引用
收藏
页码:1794 / 1803
页数:10
相关论文
共 27 条
[1]  
[Anonymous], SKIN RESURFACING
[2]   Randomized, Placebo-Controlled Study of a New Botulinum Toxin Type A for Treatment of Glabellar Lines: Efficacy and Safety [J].
Brandt, Fredric ;
Swanson, Neil ;
Baumann, Leslie ;
Huber, Barbara .
DERMATOLOGIC SURGERY, 2009, 35 (12) :1893-1901
[3]  
Carruthers A, 2004, J Clin Res, V7, P1
[4]  
Carruthers A, 2005, INT OPHTHALMOL CLIN, V45, P143
[5]   OnabotulinumtoxinA Treatment of Mild Glabellar Lines in Repose [J].
Carruthers, Alastair ;
Carruthers, Jean ;
Lei, Xiaofang ;
Pogoda, Janice M. ;
Eadie, Nina ;
Brin, Mitchell F. .
DERMATOLOGIC SURGERY, 2010, 36 (04) :2168-2171
[6]   Multicenter, Randomized, Parallel-Group Study of the Safety and Effectiveness of OnabotulinumtoxinA and Hyaluronic Acid Dermal Fillers (24-mg/mL Smooth, Cohesive Gel) Alone and in Combination for Lower Facial Rejuvenation [J].
Carruthers, Alastair ;
Carruthers, Jean ;
Monheit, Gary D. ;
Davis, Paula G. ;
Tardie, Greg .
DERMATOLOGIC SURGERY, 2010, 36 (04) :2121-2134
[7]   The effect of full-face broadband light treatments alone and in combination with bilateral crow's feet botulinum toxin type A chemodenervation [J].
Carruthers, J ;
Carruthers, A .
DERMATOLOGIC SURGERY, 2004, 30 (03) :355-366
[8]   A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines [J].
Carruthers, JA ;
Lowe, NJ ;
Menter, MA ;
Gibson, J ;
Nordquist, M ;
Mordaunt, J ;
Walker, P ;
Eadie, N .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 46 (06) :840-849
[9]   Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type a for patients with glabellar lines [J].
Carruthers, JD ;
Lowe, NJ ;
Menter, MA ;
Gibson, J ;
Eadie, N .
PLASTIC AND RECONSTRUCTIVE SURGERY, 2003, 112 (04) :1089-1098
[10]  
Cox Sue Ellen, 2005, International Ophthalmology Clinics, V45, P13, DOI 10.1097/01.iio.0000167237.49396.7b